Skip to content
ABOUT
AUTHOR GUIDELINES
AUTHORS/EDITORS
SUBSCRIPTIONS
CONTACT US
MY ACCOUNT
Facebook
X
LinkedIn
Instagram
Search
×
HOME
PSYCH. BULLETIN
LATEST ISSUE
BLACK BOOK OF DOSING & MONITORING
RATING SCALES
LICENSING INFORMATION
RESOURCES
PSYCHOTROPICS A-Z
PSYCHOPHARMACOLOGY 101
NEWS
Functional Assessment Staging (FAST)
1
x
$
0.00
Optimizing Treatment Outcomes for Patients With Depression and Generalized Anxiety Disorder
1
x
$
30.00
R. Bart Sangal, MD: What Is a Significant Response in Drug Studies of Attention- Deficit/Hyperactivity Disorder: Statistical Significance Is Necessary, But Is It Sufficient?
1
x
$
30.00
The Psychopharmacology Algorithm Project at the Harvard South Shore Psychiatry Program Bipolar Depression Algorithm
1
x
$
0.00
Correlation of 1846G>A Polymorphism of CYP2D6 Gene with Haloperidol Efficacy and Safety in Patients with Alcoholic Hallucinoses
1
x
$
30.00
View Cart
Checkout
Home
schizophrenia
Sort by
Popularity
Sort by
Name
Sort by
Price
Sort by
Date
Sort by
Popularity
Show
20 Products
Show
20 Products
Show
40 Products
Show
60 Products
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder
$
0.00
Add to cart
Details
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder
$
0.00
Add to cart
Details
Takefumi Suzuki – Treatment Target in Schizophrenia: A Critical Review and a Clinical Suggestion
$
30.00
Add to cart
Details
Quetiapine and Paediatric Psychiatrica: Evidence or Diffidence?
$
30.00
Add to cart
Details
Involuntary Facial Twitching in a Patient with Schizophrenia on Treatment with Long Acting Injectable Olanzapine
$
30.00
Add to cart
Details
George Harrison, MD: Priapism and Quetiapine: A Case Report
$
30.00
Add to cart
Details
Gender and Schizophrenia
$
0.00
Add to cart
Details
Ethical Issues In Schizophrenia: Considerations for Treatment and Research
$
0.00
Add to cart
Details
Combining Medication Adherence Support Plus Long-Acting Injectable Antipsychotic Medication: A Post-Hoc Analysis of 3 Pilot Studies
$
30.00
Add to cart
Details
Long Acting Injectables and their Correlation with Subjectivity in Schizophrenia Spectrum Disorder
$
30.00
Add to cart
Details
Psychopharmacology Bulletin VOL 49 No. 2, 2019 – Full Issue Stacked PDF
$
90.00
Add to cart
Details
Psychopharmacology Bulletin VOL 49 No. 1, 2019 – Full Issue Stacked PDF
$
90.00
Add to cart
Details
Exercise as a Treatment for Schizophrenia: A Review
$
30.00
Add to cart
Details
Psychopharmacology Bulletin VOL 47 No. 3, 2017 – Full Issue Stacked PDF
$
60.00
Add to cart
Details
Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil
$
0.00
Add to cart
Details
Sex Differences in Antipsychotic Related Metabolic Functioning in Schizophrenia Spectrum Disorders
$
30.00
Add to cart
Details
Lori Davis, MD: Clinical and Pharmacoeconomic Evaluation of Switch to Olanzapine in Veterans with Schizophrenia or Schizoaffective Disorder
$
30.00
Add to cart
Details
Vicki L. Ellingrod, PharmD, BCPP: 5-HT2A Receptor Promoter Polymorphism, -1438G/A and Negative Symptom Response to Olanzapine in Schizophrenia
$
30.00
Add to cart
Details
Vicki L. Ellingrod, PharmD, BCPP: Leptin and Leptin Receptor Gene Polymorphisms and Increases in Body Mass Index (BMI) from Olanzapine Treatment in Persons with Schizophrenia
$
30.00
Add to cart
Details
Asenapine in the Treatment of Negative Symptoms of Schizophrenia: Clinical Trial Design and Rationale
$
30.00
Add to cart
Details
Previous
1
2
3
4
Next
Page load link
Go to Top
